Thousand Oaks, CA – According to filings with the U.S. Securities and Exchange Commission, LungLife AI is raising $10,332,080.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Sara Barrington played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About LungLife AI

LungLife AI is a cancer diagnostics company focused on transforming cancer diagnosis and management through the artificial intelligence (AI) enabled molecular analysis of cancer biomarkers in blood. LungLife AI is focused upon lung cancer diagnostic solutions recognizing the need to substantially improve patient outcomes. The company’s testing methodology is designed to deliver actionable information to clinicians via minimally invasive blood draw. Our tests span all stages of lung cancer, from an aid in diagnosis for patients with suspicious lung nodules as well as treatment stratification and monitoring in late-stage lung cancer.

To learn more about LungLife AI, visit http://www.lunglifeai.com/

Contact:
Sara Barrington, Chief Executive Officer
805-409-9868
https://www.linkedin.com/in/sara-barrington-06926382/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved